Proprotein convertase enzyme FURIN is upregulated in primary Sjögren's syndrome.

Olli Silvennoinen
Olli Silvennoinen
University of Tampere
Marko Pesu
Marko Pesu
University of Tampere
Marja Pertovaara
Marja Pertovaara
Tampere University Hospital

Clin Exp Rheumatol 2018 Feb 21. Epub 2018 Feb 21.

Department of Internal Medicine, Centre for Rheumatic Diseases, Tampere University Hospital; and Faculty of Medicine and Life Sciences, University of Tampere, Finland.

Objectives: The proprotein convertase enzyme FURIN is a critical regulator of the anti-inflammatory TGFβ-1 cytokine and peripheral immune tolerance. In T cells, FURIN is co-regulated with IFN-γ and thus highly expressed in T helper 1 type cells. Previous studies have demonstrated that FURIN is upregulated in inflammatory conditions, including atherosclerosis, rheumatoid arthritis and systemic lupus erythematosus. Here, we evaluated the levels of FURIN in the plasma and peripheral blood mononuclear cells (PBMCs) of patients with primary Sjögren's syndrome (pSS) and in healthy controls.

Methods: FURIN plasma levels were determined by ELISA, and the mRNA expression in PBMCs was quantitated using qPCR. FURIN levels in the plasma were correlated with the clinical and demographic characteristics of the patients.

Results: FURIN was found to be significantly upregulated at both the protein and mRNA level in pSS patients compared to healthy controls. In pSS patients, high FURIN protein levels were significantly associated with elevated IFN-γ levels in the plasma as well as a longer duration of sicca symptoms in the eyes. pSS patients with high FURIN levels in their plasma showed a trend towards lower levels of serum beta-2 microglobulin, ESR and a lower systemic disease activity index ESSDAI.

Conclusions: The proprotein convertase FURIN is significantly upregulated in pSS. Elevated FURIN levels associate with high levels of the Th1 type cytokine IFN-γ and long duration of dry eye symptoms. Patients with high FURIN levels show signs of lower disease activity suggesting that FURIN might have a protective role in pSS.
February 2018
4 Reads

Similar Publications

Increased levels of circulating microparticles in primary Sjögren's syndrome, systemic lupus erythematosus and rheumatoid arthritis and relation with disease activity.

Arthritis Res Ther 2009 15;11(5):R156. Epub 2009 Oct 15.

Rhumatologie, Hôpital Bicêtre, Assistance Publique-Hôpitaux de Paris (AP-HP), INSERM U802, Université Paris-Sud 11, 78 rue du Général Leclerc, 94270, Le Kremlin Bicêtre, France.

Introduction: Cell stimulation leads to the shedding of phosphatidylserine (PS)-rich microparticles (MPs). Because autoimmune diseases (AIDs) are characterized by cell activation, we investigated level of circulating MPs as a possible biomarker in primary Sjögren's syndrome (pSS), systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA).

Methods: We measured plasma levels of total, platelet and leukocyte MPs by prothrombinase capture assay and flow cytometry in 43 patients with pSS, 20 with SLE and 24 with RA and in 44 healthy controls (HCs). Read More

View Article
February 2010

The expression of death decoy receptor 3 was increased in the patients with primary Sjögren's syndrome.

Clin Rheumatol 2015 May 8;34(5):879-85. Epub 2015 Jan 8.

Department of Clinical Laboratory, Zhejiang Provincial People's Hospital, 158 Shangtang Road, 310014, Hangzhou, China.

Previous studies suggested a pathological role for the death decoy receptor 3 (DcR3) in systemic lupus erythematosus (SLE) and rheumatic arthritis (RA). Herein, the expression of DcR3 in primary Sjögren's syndrome (pSS) and the relationship with clinical characteristics were investigated. The serum DcR3 levels of pSS patients and healthy controls were measured by ELISA. Read More

View Article
May 2015

Salivary cytokine profiles in primary Sjögren's syndrome differ from those in non-Sjögren sicca in terms of TNF-α levels and Th-1/Th-2 ratios.

Clin Exp Rheumatol 2011 Nov-Dec;29(6):970-6. Epub 2011 Dec 22.

Department of Internal Medicine, National University Bundang Hospital, Seoul, Republic of Korea.

Objectives: To compare salivary cytokine profiles in patients with primary Sjögren's syndrome (pSS), non-SS sicca controls, and non-sicca controls, and to investigate whether cytokine levels are correlated with clinical parameters of pSS patients.

Methods: Un-stimulated whole saliva samples were obtained from pSS patients (n=30) classified according to the criteria of the American European Consensus Group. Age- and gender-matched non-SS sicca patients (n=30) and non-sicca subjects (n=25) served as controls. Read More

View Article
March 2012

Proteomic analysis of saliva: a unique tool to distinguish primary Sjögren's syndrome from secondary Sjögren's syndrome and other sicca syndromes.

Arthritis Res Ther 2011 25;13(6):R194. Epub 2011 Nov 25.

Department of Internal Medicine, Rheumatology Unit, University of Pisa, Via Roma 67, 56126 Pisa, Italy.

Introduction: A growing interest has arisen in salivary proteomics as a tool for the identification of biomarkers for primary Sjögren's syndrome (pSS). Nonetheless, only a limited number of preclinical validation studies have been performed, limiting the possibility of translating proteomic results into clinical practice. The primary aim of this study was to refine the diagnostic power of a panel of candidate salivary biomarkers described in pSS with respect to both healthy volunteers and pathological controls. Read More

View Article
December 2012